Company: LENZ
Filing Date: 2025-09-30
Form Type: 8-K
Source: 0001815776-25-000062
Chunk: 0

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-09-30
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

OnSeptember 30, 2025, LENZ Therapeutics, Inc. (“ LENZ”) issued a press release announcing the availability of VIZZ™(aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved in the United States by the U. S. Food and Drug Administration (“ FDA”) for the treatment of presbyopia in adults. A copy of the press release is furnished herewith as Exhibit 99.1.

The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 8.01 Other Events.